Device Trial Radar · NCT05701488
SIRT With Tremelimumab and Durvalumab for Resectable HCC
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
20
Actual
Start
Apr 21, 2023
Primary completion
Oct 1, 2027
Study completion Oct 1, 2027
Sponsor
- Lead sponsor
- Jiping Wang, MD, PhDAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- AstraZeneca; Sirtex Medical
- First posted
- Jan 27, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this research study is to evaluate the safety and tolerability of tremelimumab and durvalumab with or without Selective Internal Yttrium-90 Radioembolization (SIRT) in participants with resectable hepatocellular carcinoma (HCC) who will undergo liver surgery. The names of the interventions involved in this study are: * Durvalumab (a type of immunotherapy) * Tremelimumab (a type of immunotherapy) * Selective Internal Yttrium-90 Radioembolization (SIRT) (a type of radiation microsphere bead)
Conditions
- Resectable Hepatocellular Carcinoma
- Hepatocellular Carcinoma
- Hepatocellular Cancer
Interventions
DurvalumabDrug
Intravenous infusion
TremelimumabDrug
Intravenous infusion
SIRTDevice
SIR (Selective Internal Radiation) Sphere resin microspheres, radioactive particles delivered via injection into an artery.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Adverse EventsTime frame: up to 18 months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Cedars-Sinai Medical Center
Los Angeles, California
2 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.